A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Study ID
NCT06895928
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-A2102 — DRUG
    SHR-A2102 for injection.
  • Bevacizumab Injection — DRUG
    Bevacizumab injection.
  • Adebelimab Injection — DRUG
    Adebelimab injection.
  • Ametinib Mesylate Tablets — DRUG
    Ametinib mesylate tablets.
  • Osimertinib Mesylate Tablets — DRUG
    Osimertinib mesylate tablets.

Study Details

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.

Key Dates

Start date
Mar 28, 2025
Status verified
Mar 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
400 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group

Primary Outcome Measure

Adverse events (AEs) [ Time Frame: From day 1 to 90 days after the last dose. ]

Central Contacts

Related Studies